FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related Amyloid Pathology
According to a new announcement, the FDA has given clearance to Roche’s Elecsys ptau181 test, marking it the first blood-based biomarker test available for use in primary care settings to assist in Alzheimer disease (AD) assessment and diagnosis. Through this minimally invasive test, clinicians may better identify patients in early stages of cognitive decline who